InflaRx N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IFRX | RLYB | ANNX | ARTV | CANTA.ST | ZURA | |
|---|---|---|---|---|---|---|
| Market cap | 218.10M | 85.60M | 820.88M | 206.32M | 475.36M | 387.23M |
| P/E (TTM) | — | 3.4 | — | — | 2.5 | — |
| Forward P/E | -4.0 | -2.9 | -4.0 | -2.1 | -1.8 | -5.9 |
| Price/book | 2.3 | 0.9 | 4.1 | 0.6 | 1.6 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +30.65% | +217.20% | +43.38% | +22.09% | −48.13% | +9.92% |
| Today | −8.64% | +0.25% | +3.34% | +0.48% | −2.09% | +0.75% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IFRX news ›InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Stock quotes, market indicators and the latest market news. Anti-C5a therapy in AAVA growing body of clinical data supporting the utility and safety of anti-C5a therapy in AAV has emerged in recent years. Important Safety Information about…
InflaRx Shares New Pre-Clinical Izicopan Renal Data at Kidney Week 2026
InflaRx revealed new in vivo and in vitro results for izicopan at Kidney Week 2026 hosted by the American Society of Nephrology. On October 22, 2026, InflaRx N.V. submitted a Form 6-K to the U.S. Securities and Exchange Commission…
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into i... InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026 - Data from…
InflaRx to Host Virtual Capital Markets Day
Featuring leading experts in the fields of AAV and complement inhibition, the virtual event will provide an overview of the evolving treatment landscape and unmet need in AAV, and how izicopan’s differentiated chemistry, metabolic…
InflaRx initiated with a Buy at Needham
Needham initiated coverage of InflaRx (IFRX) with a Buy rating and $8 price target InflaRx’s izicopan offers potentially significant upside in ... InflaRx initiated with a Buy at Needham Needham initiated coverage of InflaRx (IFRX) with a…
InflaRx N.V. Selected for Late-Breaking Kidney Week 2026 Poster on Izicopan Kidney Disease Models | IFRX Stock News
InflaRx N.V. announces izicopan's presentation at Kidney Week 2026, highlighting its potential for kidney disease treatment. The session will occur on October 22, 2026, from 10:00 AM to 12:00 PM at Kidney Week 2026 in Denver, Colorado.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- kalkinemedia.com1
- manilatimes.net1
- markets.financialcontent.com1
- quiverquant.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.